CSIMarket
 


Zymeworks Inc   (ZYME)
Other Ticker:  
 

Zymeworks Inc 's Leverage Ratio

ZYME's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to repayements of liabilities of -12.08% Zymeworks Inc improved Leverage Ratio in forth quarter 2023 to 0.25, below the company's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 52 other companies have achieved lower Leverage Ratio than Zymeworks Inc in the IV Quarter 2023. While Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 268, from total ranking in the third quarter 2023 at 691 .

Explain Leverage Ratio?
Who are ZYME Customers?
What are ZYME´s Total Liabilities?


ZYME Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -5.71 % 136.06 % 101.96 % 67.66 % 97.9 %
Y / Y Total Liabilities Change -25.48 % 9.56 % 4.4 % -13.78 % 11.23 %
Leverage Ratio MRQ 0.25 0.31 0.34 0.27 0.32
ZYME's Total Ranking # 268 # 691 # 818 # 275 # 790
Seq. Equity Change 9.54 % -5.47 % -5.2 % -3.94 % 174.23 %
Seq. Total Liabilities Change -12.08 % -13.79 % 20.38 % -18.34 % 29.26 %



Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 53
Healthcare Sector # 94
Overall Market # 268


Leverage Ratio Statistics
High Average Low
0.67 0.33 0.07
(Sep 30 2022)   (Sep 30 2018)




Financial Statements
Zymeworks Inc 's Equity $ 465 Millions Visit ZYME's Balance sheet
Zymeworks Inc 's Total Liabilities $ 116 Millions Visit ZYME's Balance sheet
Source of ZYME's Sales Visit ZYME's Sales by Geography


Cumulative Zymeworks Inc 's Leverage Ratio

ZYME's Leverage Ratio for the trailling 12 Months

ZYME Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -5.71 % 136.06 % 101.96 % 67.66 % 97.9 %
Y / Y Total Liabilities TTM Growth -25.48 % 9.56 % 4.4 % -13.78 % 11.23 %
Leverage Ratio TTM 0.29 0.31 0.35 0.4 0.48
Total Ranking TTM # 277 # 629 # 765 # 948 # 1275
Seq. Equity TTM Growth 9.54 % -5.47 % -5.2 % -3.94 % 174.23 %
Seq. Total Liabilities TTM Growth -12.08 % -13.79 % 20.38 % -18.34 % 29.26 %


On the trailing twelve months basis Due to repayements of liabilities of -12.08% Zymeworks Inc decreased Leverage Ratio in the 12 months ending in IV Quarter 2023 to 0.29, below the company's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry ZYME recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 192, from total ranking in previous 12 month period at 627.

Explain Leverage Ratio?
Who are ZYME Customers?
What are ZYME´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 268


trailing twelve months Leverage Ratio Statistics
High Average Low
0.59 0.35 0.21
(Sep 30 2022)   (Dec 31 2018)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Equity
Paxmedica Inc   0.68 $ 2.295  Millions$ 3.385  Millions
Acurx Pharmaceuticals inc   0.65 $ 3.042  Millions$ 4.667  Millions
Beigene ltd   0.64 $ 2,267.948  Millions$ 3,537.327  Millions
Ovid Therapeutics Inc   0.63 $ 54.984  Millions$ 87.797  Millions
23andme Holding Co  0.61 $ 231.023  Millions$ 377.188  Millions
Elite Pharmaceuticals Inc   0.61 $ 28.283  Millions$ 46.414  Millions
Nature s Sunshine Products inc   0.60 $ 95.715  Millions$ 159.540  Millions
Bicycle Therapeutics Plc  0.58 $ 215.030  Millions$ 370.932  Millions
Madrigal Pharmaceuticals Inc   0.58 $ 233.501  Millions$ 405.333  Millions
Werewolf Therapeutics Inc   0.57 $ 63.459  Millions$ 111.374  Millions
Harmony Biosciences Holdings inc   0.52 $ 244.962  Millions$ 466.992  Millions
Capricor Therapeutics inc   0.49 $ 11.113  Millions$ 22.601  Millions
Cymabay Therapeutics Inc   0.49 $ 142.430  Millions$ 292.256  Millions
Earth Science Tech Inc   0.48 $ 1.041  Millions$ 2.159  Millions
Lumos Pharma Inc   0.48 $ 13.051  Millions$ 27.305  Millions
Schrodinger Inc   0.46 $ 254.397  Millions$ 548.558  Millions
Talphera Inc   0.45 $ 6.290  Millions$ 14.105  Millions
Xencor Inc  0.42 $ 283.896  Millions$ 669.133  Millions
Arrowhead Pharmaceuticals Inc   0.42 $ 73.609  Millions$ 173.714  Millions
Oncolytics Biotech Inc   0.41 $ 8.623  Millions$ 21.113  Millions
Anaptysbio Inc   0.40 $ 35.665  Millions$ 88.103  Millions
Arcus Biosciences Inc   0.40 $ 184.000  Millions$ 462.000  Millions
Integrated Biopharma Inc  0.39 $ 7.155  Millions$ 18.566  Millions
Biomarin Pharmaceutical Inc  0.38 $ 1,890.054  Millions$ 4,951.549  Millions
Benitec Biopharma Inc   0.38 $ 5.883  Millions$ 15.470  Millions
Renovaro Inc   0.37 $ 16.328  Millions$ 43.596  Millions
Kamada Ltd   0.34 $ 83.972  Millions$ 244.021  Millions
Edesa Biotech Inc   0.33 $ 1.909  Millions$ 5.845  Millions
Anebulo Pharmaceuticals Inc   0.31 $ 2.027  Millions$ 6.487  Millions
Zai Lab Limited  0.30 $ 240.177  Millions$ 796.118  Millions

Date modified: 2024-03-07T21:16:12+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com